PN and PDRN are not the same abbreviation

1.3.1What the two terms actually denote

Deoxyribonucleotide is simply the correct chemical name for the nucleotide unit found in DNA, as distinct from the ribonucleotide unit found in RNA. So polydeoxyribonucleotide is, read literally, a chain of DNA nucleotides, which is to say a polynucleotide of the DNA type. At the level of pure nomenclature the two words overlap almost completely.

In use, the field has settled into a working convention. PDRN refers to preparations of relatively short fragments. PN refers to preparations of longer chains. Where the boundary falls is a matter of manufacturer convention rather than an agreed standard, and you will find products described both ways depending on who is doing the describing and what they are selling.

The physical consequence is real and is easy to observe. Longer chains entangle and hold water, so a PN preparation is more viscous, sits differently when injected, and produces a more noticeable immediate physical effect. A PDRN preparation is thinner and disperses more readily. Those are genuine differences in how a product behaves in tissue.

1.3.2Why the literature split matters

PDRN has been studied in contexts that have nothing to do with cosmetic treatment. Work exists in wound healing, in tissue repair, in ischaemic conditions and in ophthalmology, much of it laboratory or animal work and some of it clinical. That literature is where the mechanistic story most commonly told in clinics originates, including the account involving adenosine receptor activity.

Cosmetic polynucleotide treatment is a much more recent and much smaller field. When a clinic page describes a mechanism in confident detail and then describes a cosmetic result, there is often a silent jump between the two: the mechanism is borrowed from PDRN work in a different tissue and a different clinical problem, and the result is asserted for a PN product in facial skin. The jump might be legitimate. It is a jump nonetheless, and the reader is entitled to see it marked.

This is not a criticism unique to this sector. It is the ordinary problem of translating preclinical work into a clinical claim, and it is exactly what reporting standards and systematic review methods exist to control. The relevant point for a patient is narrower: when you are shown a study, look at what molecule was studied, in what tissue, in what species, for what condition.

1.3.3Reading a product description with this in mind

Once you know the distinction, product literature becomes considerably easier to parse. A few patterns recur.

• A page that uses PN and PDRN interchangeably within the same paragraph is not being careless about spelling. It is treating two different bodies of work as one.
• A page that asserts a specific molecular weight range as the correct or optimal one, without citing a comparative study, is asserting something that has not been established.
• A page that cites research to support a cosmetic claim, where the research concerned a different molecule in a different tissue, has made an argument by association.
• A page that describes the product only by brand name and never by what it contains has told you nothing at all.

1.3.4What this changes in practice

Very little about the treatment itself, and quite a lot about how you should read what you are told about it. The two products are close relatives, they are made in similar ways from similar material, and there is no reason to think one is dangerous and the other safe. The difference is evidentiary rather than clinical.

If a practitioner tells you the product they use is supported by research, the useful follow up is to ask which molecule the research studied and in what setting. That question is not hostile and it is not unanswerable. A practitioner who has read the material behind the product they inject will be able to answer it in a sentence, and one who has taken the manufacturer's word for it will not.

1.3.5The other abbreviations you will meet

The field generates acronyms quickly and most of them are proprietary rather than descriptive. Some name a specific manufacturer's preparation, some name a technique or an injection pattern, and a few name nothing in particular. A useful discipline is to translate every acronym you are given back into a plain statement of what is in the syringe and where it is going, and to notice when that translation cannot be made.

The same discipline applies to protocol names. A named protocol tells you about injection points and spacing, which is a matter of technique. It does not tell you anything additional about the material, and a technique name attached to a product does not extend the evidence for the product.

1.3.6In summary

PDRN describes shorter fragments and carries most of the older research, largely outside cosmetics. PN describes longer chains, is more viscous, and is what most cosmetic products in the United Kingdom contain. Any argument that moves from one to the other without saying so is an argument with a step missing. Once you can see that step, a good deal of the confident writing in this category becomes considerably easier to weigh.